Switch theme
Sign up to access all valuation multiples
Arrowhead Pharmaceuticals Inc is an American biotechnology company. Its main target is the development of medicine to treat diseases with a genetic origin, characterized by the overproduction of one or more proteins. Its medical solutions are aimed at the genes that trigger the diseases. Its portfolio includes drugs targeting cardiovascular, Cardiometabolic, Central Nervous System, Pulmonary, Liver, Muscular, and Complement Mediated Disease. It majority products are liver disease curable.
1989
609
LTM Revenue $480M
LTM EBITDA -$130M
$1.5B
Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.
Arrowhead Pharmaceuticals has a last 12-month revenue (LTM) of $480M and a last 12-month EBITDA of -$130M.
In the most recent fiscal year, Arrowhead Pharmaceuticals achieved revenue of $3.6M and an EBITDA of -$562M.
Arrowhead Pharmaceuticals expects next 12-month revenue of XXX and NTM EBITDA of XXX
See Arrowhead Pharmaceuticals valuation multiples based on analyst estimates| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue | $480M | XXX | $3.6M | XXX | XXX | XXX |
| Gross Profit | $479M | XXX | n/a | XXX | XXX | XXX |
| Gross Margin | 100% | XXX | n/a | XXX | XXX | XXX |
| EBITDA | -$130M | XXX | -$562M | XXX | XXX | XXX |
| EBITDA Margin | -27% | XXX | -15813% | XXX | XXX | XXX |
| EBIT | -$166M | XXX | -$601M | XXX | XXX | XXX |
| EBIT Margin | -35% | XXX | -16927% | XXX | XXX | XXX |
| Net Profit | -$188M | XXX | -$599M | XXX | XXX | XXX |
| Net Margin | -39% | XXX | -16882% | XXX | XXX | XXX |
| Net Debt | XXX | XXX | $290M | XXX | XXX | XXX |
Financial data powered by Morningstar, Inc.
As of May 30, 2025, Arrowhead Pharmaceuticals's stock price is $16.
Arrowhead Pharmaceuticals has current market cap of $2.2B, and EV of $1.5B.
See Arrowhead Pharmaceuticals trading valuation data| EV | Market Cap | Price 1D | Price 1M | Price 3M | Price 12M | EPS |
|---|---|---|---|---|---|---|
| $1.5B | $2.2B | XXX | XXX | XXX | XXX | $-1.56 |
Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more
Start Free TrialAs of May 30, 2025, Arrowhead Pharmaceuticals has market cap of $2.2B and EV of $1.5B.
Arrowhead Pharmaceuticals's trades at 8.3x EV/Revenue multiple, and -3.8x EV/EBITDA.
Equity research analysts estimate Arrowhead Pharmaceuticals's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX
Arrowhead Pharmaceuticals has a P/E ratio of -11.8x.
See valuation multiples for Arrowhead Pharmaceuticals and 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Market cap (current) | $2.2B | XXX | $2.2B | XXX | XXX | XXX |
| EV (current) | $1.5B | XXX | $1.5B | XXX | XXX | XXX |
| EV/Revenue | 3.1x | XXX | 8.3x | XXX | XXX | XXX |
| EV/EBITDA | -11.6x | XXX | -3.8x | XXX | XXX | XXX |
| EV/EBIT | -9.1x | XXX | -3.4x | XXX | XXX | XXX |
| EV/Gross Profit | 3.2x | XXX | n/a | XXX | XXX | XXX |
| P/E | -11.8x | XXX | -5.0x | XXX | XXX | XXX |
| EV/FCF | 46.6x | XXX | -4.1x | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.
Start Free TrialArrowhead Pharmaceuticals's last 12 month revenue growth is -11%
Arrowhead Pharmaceuticals's revenue per employee in the last FY averaged $6K, while opex per employee averaged $1.0M for the same period.
Arrowhead Pharmaceuticals's rule of 40 is -161% (metric relevant for SaaS companies only, counted as combined revenue growth rate and EBITDA margin).
Arrowhead Pharmaceuticals's rule of X is -54% (created by Bessemer, rule of X is another metric relevant for SaaS companies only, ~1.5x stronger vs. the traditional Rule of 40, counted as revenue growth rate multiplied by 2.5 plus EBITDA margin).
See operational valuation multiples for Arrowhead Pharmaceuticals and other 12K+ public comps| LTM | NTM | Last FY | FY 2025 | FY 2026 | FY 2027 | |
|---|---|---|---|---|---|---|
| Revenue Growth | -11% | XXX | 25% | XXX | XXX | XXX |
| EBITDA Margin | -27% | XXX | -217% | XXX | XXX | XXX |
| EBITDA Growth | 75% | XXX | n/a | XXX | XXX | XXX |
| Rule of 40 | -161% | XXX | -228% | XXX | XXX | XXX |
| Bessemer Rule of X | XXX | XXX | -54% | XXX | XXX | XXX |
| Revenue per Employee | XXX | XXX | $6K | XXX | XXX | XXX |
| Opex per Employee | XXX | XXX | $1.0M | XXX | XXX | XXX |
| S&M Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| G&A Expenses to Revenue | XXX | XXX | n/a | XXX | XXX | XXX |
| R&D Expenses to Revenue | XXX | XXX | 14246% | XXX | XXX | XXX |
| Opex to Revenue | XXX | XXX | 17027% | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc. and Morningstar, Inc.
Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!
| EV/Revenue | EV/EBITDA | |||||
|---|---|---|---|---|---|---|
| 2025E | 2026E | 2027E | 2025E | 2026E | 2027E | |
| Julphar | XXX | XXX | XXX | XXX | XXX | XXX |
| Benevolent AI | XXX | XXX | XXX | XXX | XXX | XXX |
| Galapagos | XXX | XXX | XXX | XXX | XXX | XXX |
| Pharming | XXX | XXX | XXX | XXX | XXX | XXX |
| Vivoryon Therapeutics | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
| XXXXXXXX | XXX | XXX | XXX | XXX | XXX | XXX |
Valuation data powered by FactSet, Inc.
Arrowhead Pharmaceuticals acquired XXX companies to date.
Last acquisition by Arrowhead Pharmaceuticals was XXXXXXXX, XXXXX XXXXX XXXXXX . Arrowhead Pharmaceuticals acquired XXXXXXXX for XXX (EV/Revenue multiple of XXX ).
See M&A valuation multiples| Acquired Company | EV | EV/Revenue | EV/EBITDA |
|---|---|---|---|
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
| XXXXXXXXX | XXX | XXX | XXX |
Sign up to see revenue and EBITDA valuation multiples for 60K+ M&A deals.
Start Free Trial| When was Arrowhead Pharmaceuticals founded? | Arrowhead Pharmaceuticals was founded in 1989. |
| Where is Arrowhead Pharmaceuticals headquartered? | Arrowhead Pharmaceuticals is headquartered in United States of America. |
| How many employees does Arrowhead Pharmaceuticals have? | As of today, Arrowhead Pharmaceuticals has 609 employees. |
| Who is the CEO of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's CEO is Dr. Christopher Anzalone,PhD. |
| Is Arrowhead Pharmaceuticals publicy listed? | Yes, Arrowhead Pharmaceuticals is a public company listed on NAS. |
| What is the stock symbol of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals trades under ARWR ticker. |
| When did Arrowhead Pharmaceuticals go public? | Arrowhead Pharmaceuticals went public in 1997. |
| Who are competitors of Arrowhead Pharmaceuticals? | Similar companies to Arrowhead Pharmaceuticals include e.g. Julphar, Benevolent AI, Galapagos, Pharming. |
| What is the current market cap of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's current market cap is $2.2B |
| What is the current revenue of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's last 12 months revenue is $480M. |
| What is the current revenue growth of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals revenue growth (NTM/LTM) is -11%. |
| What is the current EV/Revenue multiple of Arrowhead Pharmaceuticals? | Current revenue multiple of Arrowhead Pharmaceuticals is 3.1x. |
| Is Arrowhead Pharmaceuticals profitable? | Yes, Arrowhead Pharmaceuticals is EBITDA-positive (as of the last 12 months). |
| What is the current EBITDA of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's last 12 months EBITDA is -$130M. |
| What is Arrowhead Pharmaceuticals's EBITDA margin? | Arrowhead Pharmaceuticals's last 12 months EBITDA margin is -27%. |
| What is the current EV/EBITDA multiple of Arrowhead Pharmaceuticals? | Current EBITDA multiple of Arrowhead Pharmaceuticals is -11.6x. |
| What is the current FCF of Arrowhead Pharmaceuticals? | Arrowhead Pharmaceuticals's last 12 months FCF is $32.3M. |
| What is Arrowhead Pharmaceuticals's FCF margin? | Arrowhead Pharmaceuticals's last 12 months FCF margin is 7%. |
| What is the current EV/FCF multiple of Arrowhead Pharmaceuticals? | Current FCF multiple of Arrowhead Pharmaceuticals is 46.6x. |
Get access to always up-to-date, precisely categorized 70K+ public and private valuation multiples, across tech and beyond.
